Assessment of Exposure–Response with Recommended Dose of Entrectinib in Patients with Advanced/ Metastatic Solid Tumors
Latest Information Update: 20 Oct 2020
At a glance
- Drugs Entrectinib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 20 Oct 2020 New trial record
- 23 Sep 2020 Results (n=276) assessing population PK model for pharmacokinetic analysis of Entrectinib, presented at the 2020 American College of Clinical Pharmacology Annual Meeting
- 23 Sep 2020 Results presented at the 2020 American College of Clinical Pharmacology Annual Meeting